![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: INTS6 |
Gene summary for INTS6 |
![]() |
Gene information | Species | Human | Gene symbol | INTS6 | Gene ID | 26512 |
Gene name | integrator complex subunit 6 | |
Gene Alias | DBI-1 | |
Cytomap | 13q14.3 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9UL03 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
26512 | INTS6 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.97e-09 | -4.65e-01 | 0.0155 |
26512 | INTS6 | HTA11_866_3004761011 | Human | Colorectum | AD | 7.87e-05 | -4.45e-01 | 0.096 |
26512 | INTS6 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.45e-08 | -4.53e-01 | 0.0674 |
26512 | INTS6 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 4.71e-09 | -4.48e-01 | 0.3005 |
26512 | INTS6 | A001-C-207 | Human | Colorectum | FAP | 3.14e-02 | -3.42e-01 | 0.1278 |
26512 | INTS6 | A015-C-203 | Human | Colorectum | FAP | 3.22e-19 | -4.77e-01 | -0.1294 |
26512 | INTS6 | A015-C-204 | Human | Colorectum | FAP | 6.46e-05 | -4.28e-01 | -0.0228 |
26512 | INTS6 | A002-C-201 | Human | Colorectum | FAP | 4.93e-09 | -4.07e-01 | 0.0324 |
26512 | INTS6 | A002-C-203 | Human | Colorectum | FAP | 8.35e-05 | -2.81e-01 | 0.2786 |
26512 | INTS6 | A001-C-119 | Human | Colorectum | FAP | 4.18e-06 | -4.59e-01 | -0.1557 |
26512 | INTS6 | A001-C-108 | Human | Colorectum | FAP | 5.67e-14 | -4.11e-01 | -0.0272 |
26512 | INTS6 | A002-C-205 | Human | Colorectum | FAP | 4.28e-16 | -5.14e-01 | -0.1236 |
26512 | INTS6 | A001-C-104 | Human | Colorectum | FAP | 9.47e-04 | -3.50e-01 | 0.0184 |
26512 | INTS6 | A015-C-006 | Human | Colorectum | FAP | 1.79e-07 | -4.05e-01 | -0.0994 |
26512 | INTS6 | A015-C-106 | Human | Colorectum | FAP | 1.98e-07 | -3.91e-01 | -0.0511 |
26512 | INTS6 | A002-C-114 | Human | Colorectum | FAP | 4.11e-10 | -3.62e-01 | -0.1561 |
26512 | INTS6 | A015-C-104 | Human | Colorectum | FAP | 2.52e-19 | -4.41e-01 | -0.1899 |
26512 | INTS6 | A001-C-014 | Human | Colorectum | FAP | 1.93e-10 | -3.84e-01 | 0.0135 |
26512 | INTS6 | A002-C-016 | Human | Colorectum | FAP | 3.37e-10 | -3.77e-01 | 0.0521 |
26512 | INTS6 | A015-C-002 | Human | Colorectum | FAP | 2.82e-07 | -4.32e-01 | -0.0763 |
Page: 1 2 3 4 5 6 7 8 9 10 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Cervix | N_HPV | ![]() |
Endometrium | AEH | ![]() |
Endometrium | EEC | ![]() |
Prostate | BPH | ![]() |
Prostate | Tumor | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00344707 | Endometrium | AEH | ncRNA processing | 62/2100 | 395/18723 | 3.93e-03 | 2.65e-02 | 62 |
GO:003447012 | Endometrium | EEC | ncRNA processing | 63/2168 | 395/18723 | 5.20e-03 | 3.26e-02 | 63 |
GO:003447015 | Esophagus | ESCC | ncRNA processing | 300/8552 | 395/18723 | 3.09e-35 | 3.26e-32 | 300 |
GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
GO:00311233 | Esophagus | ESCC | RNA 3'-end processing | 76/8552 | 116/18723 | 1.25e-05 | 1.15e-04 | 76 |
GO:00344704 | Liver | NAFLD | ncRNA processing | 57/1882 | 395/18723 | 3.34e-03 | 2.93e-02 | 57 |
GO:00344701 | Liver | Cirrhotic | ncRNA processing | 158/4634 | 395/18723 | 1.09e-11 | 6.96e-10 | 158 |
GO:00346603 | Liver | Cirrhotic | ncRNA metabolic process | 173/4634 | 485/18723 | 3.64e-08 | 1.21e-06 | 173 |
GO:0031123 | Liver | Cirrhotic | RNA 3'-end processing | 42/4634 | 116/18723 | 3.85e-03 | 2.10e-02 | 42 |
GO:00344702 | Liver | HCC | ncRNA processing | 293/7958 | 395/18723 | 4.26e-38 | 6.76e-35 | 293 |
GO:00346601 | Liver | HCC | ncRNA metabolic process | 332/7958 | 485/18723 | 1.48e-31 | 7.80e-29 | 332 |
GO:00311231 | Liver | HCC | RNA 3'-end processing | 81/7958 | 116/18723 | 2.27e-09 | 6.32e-08 | 81 |
GO:00344703 | Liver | Cyst | ncRNA processing | 25/496 | 395/18723 | 5.78e-05 | 3.01e-03 | 25 |
GO:00346602 | Liver | Cyst | ncRNA metabolic process | 28/496 | 485/18723 | 1.05e-04 | 4.67e-03 | 28 |
GO:00344709 | Oral cavity | OSCC | ncRNA processing | 263/7305 | 395/18723 | 4.38e-29 | 2.78e-26 | 263 |
GO:00346605 | Oral cavity | OSCC | ncRNA metabolic process | 296/7305 | 485/18723 | 2.94e-23 | 6.65e-21 | 296 |
GO:00311232 | Oral cavity | OSCC | RNA 3'-end processing | 75/7305 | 116/18723 | 1.93e-08 | 3.79e-07 | 75 |
GO:003447014 | Oral cavity | LP | ncRNA processing | 184/4623 | 395/18723 | 1.20e-21 | 3.12e-19 | 184 |
GO:003466011 | Oral cavity | LP | ncRNA metabolic process | 205/4623 | 485/18723 | 6.46e-18 | 1.09e-15 | 205 |
GO:003112311 | Oral cavity | LP | RNA 3'-end processing | 48/4623 | 116/18723 | 5.51e-05 | 7.58e-04 | 48 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
INTS6 | SNV | Missense_Mutation | novel | c.1481N>T | p.Ser494Leu | p.S494L | Q9UL03 | protein_coding | deleterious(0.01) | probably_damaging(0.947) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
INTS6 | SNV | Missense_Mutation | c.164N>C | p.Phe55Ser | p.F55S | Q9UL03 | protein_coding | deleterious(0.05) | benign(0.007) | TCGA-A2-A0CL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
INTS6 | SNV | Missense_Mutation | c.2059N>G | p.Thr687Ala | p.T687A | Q9UL03 | protein_coding | tolerated(0.53) | benign(0) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
INTS6 | SNV | Missense_Mutation | c.1237N>C | p.Glu413Gln | p.E413Q | Q9UL03 | protein_coding | tolerated(0.27) | possibly_damaging(0.809) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
INTS6 | SNV | Missense_Mutation | novel | c.1153N>G | p.Asn385Asp | p.N385D | Q9UL03 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
INTS6 | SNV | Missense_Mutation | c.520N>T | p.Arg174Trp | p.R174W | Q9UL03 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
INTS6 | SNV | Missense_Mutation | c.1904T>G | p.Val635Gly | p.V635G | Q9UL03 | protein_coding | deleterious(0.01) | possibly_damaging(0.843) | TCGA-AO-A1KR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
INTS6 | SNV | Missense_Mutation | c.902N>A | p.Arg301His | p.R301H | Q9UL03 | protein_coding | deleterious(0.01) | benign(0.433) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
INTS6 | SNV | Missense_Mutation | c.1653T>A | p.Asn551Lys | p.N551K | Q9UL03 | protein_coding | tolerated(0.57) | benign(0.206) | TCGA-E2-A1IO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | |
INTS6 | SNV | Missense_Mutation | c.1903N>C | p.Val635Leu | p.V635L | Q9UL03 | protein_coding | tolerated(0.11) | benign(0.056) | TCGA-E2-A1LH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |